Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxis [1]

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 90, Issue 1, 2005, Pages

  Bala, P ^a   Ryan, C A ^a   Murphy, B P ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

BRONCHIOLITIS; COST BENEFIT ANALYSIS; DRUG COST; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE UNIT; LENGTH OF STAY; LETTER; MAJOR CLINICAL STUDY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; IRELAND; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 11144316751     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2003.036012     Document Type: Letter

References (1)

1. The Impact Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high infants. Pediatrics 1998;102:531-7.